Cargando…

Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion

Study Design Randomized controlled trial. Objective The aim of this study was to assess the efficacy of the bone grafting substitute silicate-substituted calcium phosphate (SiCaP) compared with recombinant human bone morphogenetic protein 2 (rhBMP-2) and to evaluate the clinical outcomes over a peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Licina, Paul, Coughlan, Marc, Johnston, Emma, Pearcy, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671893/
https://www.ncbi.nlm.nih.gov/pubmed/26682097
http://dx.doi.org/10.1055/s-0035-1566230
_version_ 1782404463401631744
author Licina, Paul
Coughlan, Marc
Johnston, Emma
Pearcy, Mark
author_facet Licina, Paul
Coughlan, Marc
Johnston, Emma
Pearcy, Mark
author_sort Licina, Paul
collection PubMed
description Study Design Randomized controlled trial. Objective The aim of this study was to assess the efficacy of the bone grafting substitute silicate-substituted calcium phosphate (SiCaP) compared with recombinant human bone morphogenetic protein 2 (rhBMP-2) and to evaluate the clinical outcomes over a period of 2 years. Methods Patients undergoing PLF surgery for DDD at a single center were recruited and randomized to one of two groups: SiCaP (n = 9) or rhBMP-2 (n = 10). One patient withdrew prior to randomization and another from the rhBMP-2 group after randomization. The radiologic and clinical outcomes were examined and compared. Fusion was assessed at 12 months with computed tomography and plain radiographs. Clinical outcomes were evaluated by recording measures of pain, quality of life, disability, and neurologic status from 6 weeks to 2 years postoperatively. Results In the SiCaP and rhBMP-2 groups, fusion was observed in 9/9 and 8/9 patients, respectively. Pain and disability scores were reduced and quality of life increased in both groups. Leg pain, disability, and satisfaction scores were similar between the groups at each postoperative point; however, back pain was less at 6 weeks and quality of life was higher at 6 months in the SiCaP group than the rhBMP-2 group. Conclusions SiCaP and rhBMP-2 were comparable in terms of achieving successful bone growth and fusion. Both groups achieved similar alleviation of pain and improved quality of life and neurologic, satisfaction, and return to work outcomes following PLF surgery.
format Online
Article
Text
id pubmed-4671893
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-46718932015-12-17 Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion Licina, Paul Coughlan, Marc Johnston, Emma Pearcy, Mark Global Spine J Article Study Design Randomized controlled trial. Objective The aim of this study was to assess the efficacy of the bone grafting substitute silicate-substituted calcium phosphate (SiCaP) compared with recombinant human bone morphogenetic protein 2 (rhBMP-2) and to evaluate the clinical outcomes over a period of 2 years. Methods Patients undergoing PLF surgery for DDD at a single center were recruited and randomized to one of two groups: SiCaP (n = 9) or rhBMP-2 (n = 10). One patient withdrew prior to randomization and another from the rhBMP-2 group after randomization. The radiologic and clinical outcomes were examined and compared. Fusion was assessed at 12 months with computed tomography and plain radiographs. Clinical outcomes were evaluated by recording measures of pain, quality of life, disability, and neurologic status from 6 weeks to 2 years postoperatively. Results In the SiCaP and rhBMP-2 groups, fusion was observed in 9/9 and 8/9 patients, respectively. Pain and disability scores were reduced and quality of life increased in both groups. Leg pain, disability, and satisfaction scores were similar between the groups at each postoperative point; however, back pain was less at 6 weeks and quality of life was higher at 6 months in the SiCaP group than the rhBMP-2 group. Conclusions SiCaP and rhBMP-2 were comparable in terms of achieving successful bone growth and fusion. Both groups achieved similar alleviation of pain and improved quality of life and neurologic, satisfaction, and return to work outcomes following PLF surgery. Georg Thieme Verlag KG 2015-12 /pmc/articles/PMC4671893/ /pubmed/26682097 http://dx.doi.org/10.1055/s-0035-1566230 Text en © Thieme Medical Publishers
spellingShingle Article
Licina, Paul
Coughlan, Marc
Johnston, Emma
Pearcy, Mark
Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title_full Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title_fullStr Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title_full_unstemmed Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title_short Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion
title_sort comparison of silicate-substituted calcium phosphate (actifuse) with recombinant human bone morphogenetic protein-2 (infuse) in posterolateral instrumented lumbar fusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671893/
https://www.ncbi.nlm.nih.gov/pubmed/26682097
http://dx.doi.org/10.1055/s-0035-1566230
work_keys_str_mv AT licinapaul comparisonofsilicatesubstitutedcalciumphosphateactifusewithrecombinanthumanbonemorphogeneticprotein2infuseinposterolateralinstrumentedlumbarfusion
AT coughlanmarc comparisonofsilicatesubstitutedcalciumphosphateactifusewithrecombinanthumanbonemorphogeneticprotein2infuseinposterolateralinstrumentedlumbarfusion
AT johnstonemma comparisonofsilicatesubstitutedcalciumphosphateactifusewithrecombinanthumanbonemorphogeneticprotein2infuseinposterolateralinstrumentedlumbarfusion
AT pearcymark comparisonofsilicatesubstitutedcalciumphosphateactifusewithrecombinanthumanbonemorphogeneticprotein2infuseinposterolateralinstrumentedlumbarfusion